0001415889-23-013339.txt : 20230918
0001415889-23-013339.hdr.sgml : 20230918
20230918172623
ACCESSION NUMBER: 0001415889-23-013339
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230915
FILED AS OF DATE: 20230918
DATE AS OF CHANGE: 20230918
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Velleca Mark A.
CENTRAL INDEX KEY: 0001706847
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39200
FILM NUMBER: 231261934
MAIL ADDRESS:
STREET 1: 79 TW ALEXANDER DRIVE
STREET 2: 4501 RESEARCH COMMONS, SUITE 100
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701541
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-417-5868
MAIL ADDRESS:
STREET 1: ONE MAIN STREET, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aset Therapeutics, Inc.
DATE OF NAME CHANGE: 20170321
4
1
form4-09182023_090915.xml
X0508
4
2023-09-15
0001701541
Black Diamond Therapeutics, Inc.
BDTX
0001706847
Velleca Mark A.
C/O BLACK DIAMOND THERAPEUTICS, INC.
ONE MAIN STREET, 14TH FLOOR
CAMBRIDGE
MA
02142
true
true
false
false
PRESIDENT & CEO
0
Common Stock
2023-09-15
4
A
0
5208
3.60
A
46522
D
Stock Option (Right to Buy)
3.55
2023-09-17
4
A
0
1000000
0
A
2033-09-16
Common Stock
1000000
1000000
D
These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023.
25% of the shares subject to this option shall vest and become exercisable on September 17, 2024, with the remainder vesting in 36 equal monthly installments thereafter.
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
2023-09-18